These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1328 related items for PubMed ID: 15993917

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques.
    Edghill-Smith Y, Venzon D, Karpova T, McNally J, Nacsa J, Tsai WP, Tryniszewska E, Moniuszko M, Manischewitz J, King LR, Snodgrass SJ, Parrish J, Markham P, Sowers M, Martin D, Lewis MG, Berzofsky JA, Belyakov IM, Moss B, Tartaglia J, Bray M, Hirsch V, Golding H, Franchini G.
    J Infect Dis; 2003 Oct 15; 188(8):1181-91. PubMed ID: 14551889
    [Abstract] [Full Text] [Related]

  • 26. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone.
    Meseda CA, Elkins KL, Merchlinsky MJ, Weir JP.
    J Infect Dis; 2002 Oct 15; 186(8):1065-73. PubMed ID: 12355355
    [Abstract] [Full Text] [Related]

  • 27. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.
    Stittelaar KJ, van Amerongen G, Kondova I, Kuiken T, van Lavieren RF, Pistoor FH, Niesters HG, van Doornum G, van der Zeijst BA, Mateo L, Chaplin PJ, Osterhaus AD.
    J Virol; 2005 Jun 15; 79(12):7845-51. PubMed ID: 15919938
    [Abstract] [Full Text] [Related]

  • 28. Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA).
    Abdalrhman I, Gurt I, Katz E.
    Vaccine; 2006 May 08; 24(19):4152-60. PubMed ID: 16603280
    [Abstract] [Full Text] [Related]

  • 29. Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination.
    Kennedy JS, Frey SE, Yan L, Rothman AL, Cruz J, Newman FK, Orphin L, Belshe RB, Ennis FA.
    J Infect Dis; 2004 Oct 01; 190(7):1286-94. PubMed ID: 15346340
    [Abstract] [Full Text] [Related]

  • 30. Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax.
    Davies DH, Wyatt LS, Newman FK, Earl PL, Chun S, Hernandez JE, Molina DM, Hirst S, Moss B, Frey SE, Felgner PL.
    J Virol; 2008 Jan 01; 82(2):652-63. PubMed ID: 17977963
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Genomic differences of Vaccinia virus clones from Dryvax smallpox vaccine: the Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3.
    Osborne JD, Da Silva M, Frace AM, Sammons SA, Olsen-Rasmussen M, Upton C, Buller RM, Chen N, Feng Z, Roper RL, Liu J, Pougatcheva S, Chen W, Wohlhueter RM, Esposito JJ.
    Vaccine; 2007 Dec 17; 25(52):8807-32. PubMed ID: 18037545
    [Abstract] [Full Text] [Related]

  • 34. Monitoring of human immunological responses to vaccinia virus.
    Harrop R, Ryan MG, Golding H, Redchenko I, Carroll MW.
    Methods Mol Biol; 2004 Dec 17; 269():243-66. PubMed ID: 15114020
    [Abstract] [Full Text] [Related]

  • 35. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
    Hodge JW, Poole DJ, Aarts WM, Gómez Yafal A, Gritz L, Schlom J.
    Cancer Res; 2003 Nov 15; 63(22):7942-9. PubMed ID: 14633725
    [Abstract] [Full Text] [Related]

  • 36. Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate.
    Ferrier-Rembert A, Drillien R, Meignier B, Garin D, Crance JM.
    Vaccine; 2007 Nov 28; 25(49):8290-7. PubMed ID: 17964011
    [Abstract] [Full Text] [Related]

  • 37. Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice.
    Melamed S, Paran N, Katz L, Ben-Nathan D, Israely T, Schneider P, Levin R, Lustig S.
    Vaccine; 2007 Nov 07; 25(45):7743-53. PubMed ID: 17928110
    [Abstract] [Full Text] [Related]

  • 38. E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox.
    Volz A, Jany S, Freudenstein A, Lantermann M, Ludwig H, Sutter G.
    Viruses; 2018 Jan 04; 10(1):. PubMed ID: 29300297
    [Abstract] [Full Text] [Related]

  • 39. Modified vaccinia Ankara: potential as an alternative smallpox vaccine.
    McCurdy LH, Larkin BD, Martin JE, Graham BS.
    Clin Infect Dis; 2004 Jun 15; 38(12):1749-53. PubMed ID: 15227622
    [Abstract] [Full Text] [Related]

  • 40. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
    Pittman PR, Hahn M, Lee HS, Koca C, Samy N, Schmidt D, Hornung J, Weidenthaler H, Heery CR, Meyer TPH, Silbernagl G, Maclennan J, Chaplin P.
    N Engl J Med; 2019 Nov 14; 381(20):1897-1908. PubMed ID: 31722150
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 67.